I read this https://www.mdpi.com/2076-2615/13/7/1261?fbclid=IwY2xjawE9AuBleHRuA2FlbQIxMQABHVHuF84kzc9ItCK07PVoNFTh_U-h61kvIb_T7uRWteoho02XOxSu1X96rg_aem_W-89cTx8m5zMvzyoByVvSQ here yesterday and thought it might interest you;
The use of omeprazole in the prevention of ESGD is a well described and common practice [211]. The idea of a ‘set and forget’ preventative plan using omeprazole should be avoided whenever possible, as this strategy has been shown to fail in more than 20% of Thoroughbred racehorses [211]. Further, omeprazole has been shown to induce its own metabolism in humans and, consistent with this, omeprazole has shown to have a reduced area under the curve (AUC) and maximal concentration (Cmax) on day 29 of treatment when compared to day 1 in horses [212]. Another study showed a decreased efficacy for ESGD prevention in horses treated for 90 days [213]. Therefore, the long-term use of omeprazole to prevent ESGD is not recommended without the significant application of other management factor alterations first and appropriate monitoring.
The use of long-term, low-dose omeprazole therapy for the prevention of EGGD has not been validated. Furthermore, pharmacodynamic work suggests that low-dose omeprazole is unlikely to consistently induce adequate acid suppression to have protective effects at the level of the glandular mucosa [143]. Instead, the authors’ preference is the use of ‘pulse therapy’ with PPIs only administered at times of significant risk, such as competition or long-distance travel. This approach is supported by a recent study that demonstrated that using omeprazole therapy during periods of stress decreased the prevalence of undifferentiated EGUS [37].